Darren L Smith

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9539012/publications.pdf

Version: 2024-02-01

270111 263392 3,681 46 25 45 citations h-index g-index papers 50 50 50 7652 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infectious Diseases, The, 2022, 22, 35-42.	4.6	612
2	The role of viral genomics in understanding COVID-19 outbreaks in long-term care facilities. Lancet Microbe, The, 2022, 3, e151-e158.	3.4	25
3	Optimisation and Application of a Novel Method to Identify Bacteriophages in Maternal Milk and Infant Stool Identifies Host-Phage Communities Within Preterm Infant Gut. Frontiers in Pediatrics, 2022, 10, 856520.	0.9	2
4	Gut Microbial Stability is Associated with Greater Endurance Performance in Athletes Undertaking Dietary Periodization. MSystems, 2022, 7, e0012922.	1.7	12
5	The Impact of <i>NOD2</i> Genetic Variants on the Gut Mycobiota in Crohn's Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation. Journal of Crohn's and Colitis, 2021, 15, 800-812.	0.6	22
6	The phage defence island of a multidrug resistant plasmid uses both BREX and type IV restriction for complementary protection from viruses. Nucleic Acids Research, 2021, 49, 11257-11273.	6.5	52
7	The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: An open-label randomised crossover study (AZTEC-CF). Journal of Cystic Fibrosis, 2021, 20, 994-1002.	0.3	8
8	SARS-CoV-2 evolution during treatment of chronic infection. Nature, 2021, 592, 277-282.	13.7	802
9	Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health, The, 2021, 6, e335-e345.	4.7	269
10	Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Reports, 2021, 35, 109292.	2.9	375
11	The impact of viral mutations on recognition by SARS-CoV-2 specific TÂcells. IScience, 2021, 24, 103353.	1.9	57
12	Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. Science, 2021, 374, eabl9551.	6.0	111
13	Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy. Annals of Clinical Microbiology and Antimicrobials, 2021, 20, 85.	1.7	23
14	Acquisition and Development of the Extremely Preterm Infant Microbiota Across Multiple Anatomical Sites. Journal of Pediatric Gastroenterology and Nutrition, 2020, 70, 12-19.	0.9	16
15	YerA41, a Yersinia ruckeri Bacteriophage: Determination of a Non-Sequencable DNA Bacteriophage Genome via RNA-Sequencing. Viruses, 2020, 12, 620.	1.5	7
16	Temperate Bacteriophages from Chronic Pseudomonas aeruginosa Lung Infections Show Disease-Specific Changes in Host Range and Modulate Antimicrobial Susceptibility. MSystems, 2019, 4, .	1.7	38
17	Comparison of temperate bacteriophages of Pseudomonas aeruginosa from the lungs of chronically infected non-cystic fibrosis bronchiectasis patients over a period 10 years. Access Microbiology, 2019, 1, .	0.2	О
18	Genome-based classification of micromonosporae with a focus on their biotechnological and ecological potential. Scientific Reports, 2018, 8, 525.	1.6	102

#	Article	IF	CITATIONS
19	Virulence factors of Moraxella catarrhalis outer membrane vesicles are major targets for cross-reactive antibodies and have adapted during evolution. Scientific Reports, 2018, 8, 4955.	1.6	26
20	Response: Commentary: Reducing Viability Bias in Analysis of Gut Microbiota in Preterm Infants at Risk of NEC and Sepsis. Frontiers in Cellular and Infection Microbiology, 2018, 8, 374.	1.8	3
21	The involvement of the low-oxygen-activated locus of Burkholderia cenocepacia in adaptation during cystic fibrosis infection. Scientific Reports, 2018, 8, 13386.	1.6	7
22	The effect of the timing of exposure to Campylobacter jejuni on the gut microbiome and inflammatory responses of broiler chickens. Microbiome, 2018, 6, 88.	4.9	104
23	Shigatoxin encoding Bacteriophage i-24B modulates bacterial metabolism to raise antimicrobial tolerance. Scientific Reports, 2017, 7, 40424.	1.6	19
24	Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis. European Journal of Medicinal Chemistry, 2017, 127, 147-158.	2.6	25
25	The temperate Burkholderia phage AP3 of the Peduovirinae shows efficient antimicrobial activity against B. cenocepacia of the IIIA lineage. Applied Microbiology and Biotechnology, 2017, 101, 1203-1216.	1.7	15
26	Reducing Viability Bias in Analysis of Gut Microbiota in Preterm Infants at Risk of NEC and Sepsis. Frontiers in Cellular and Infection Microbiology, 2017, 7, 237.	1.8	42
27	Genomic analysis of endemic clones of toxigenic and non-toxigenic Corynebacterium diphtheriae in Belarus during and after the major epidemic in 1990s. BMC Genomics, 2017, 18, 873.	1.2	41
28	Yersinia enterocolitica-Specific Infection by Bacteriophages TG1 and ï•R1-RT Is Dependent on Temperature-Regulated Expression of the Phage Host Receptor OmpF. Applied and Environmental Microbiology, 2016, 82, 5340-5353.	1.4	44
29	Towards a rational design of solid drug nanoparticles with optimised pharmacological properties. Journal of Interdisciplinary Nanomedicine, 2016, 1, 110-123.	3.6	17
30	Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. Nature Communications, 2016, 7, 13184.	5.8	44
31	A metagenomic approach to characterize temperate bacteriophage populations from Cystic Fibrosis and non-Cystic Fibrosis bronchiectasis patients. Frontiers in Microbiology, 2015, 6, 97.	1.5	19
32	Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles. Molecular Pharmaceutics, 2015, 12, 3556-3568.	2.3	15
33	Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation. Advanced Healthcare Materials, 2014, 3, 400-411.	3.9	73
34	Polymicrobial airway bacterial communities in adult bronchiectasis patients. BMC Microbiology, 2014, 14, 130.	1.3	50
35	Comparative genomics of Shiga toxin encoding bacteriophages. BMC Genomics, 2012, 13, 311.	1.2	98
36	Short communication: Characterization of Shiga toxin 2-carrying bacteriophages induced from Shiga-toxigenic Escherichia coli isolated from Italian dairy products. Journal of Dairy Science, 2012, 95, 6949-6956.	1.4	2

#	Article	IF	CITATIONS
37	Multicomponent Organic Nanoparticles for Fluorescence Studies in Biological Systems. Advanced Functional Materials, 2012, 22, 2469-2478.	7.8	56
38	Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir. Antimicrobial Agents and Chemotherapy, 2011, 55, 879-887.	1.4	58
39	454-Pyrosequencing: A Molecular Battiscope for Freshwater Viral Ecology. Genes, 2010, 1, 210-226.	1.0	14
40	Identification of Carbohydrate Metabolism Genes in the Metagenome of a Marine Biofilm Community Shown to Be Dominated by Gammaproteobacteria and Bacteroidetes. Genes, 2010, 1, 371-384.	1.0	82
41	High-Throughput Method for Rapid Induction of Prophages from Lysogens and Its Application in the Study of Shiga Toxin-Encoding <i>Escherichia coli</i> I> Strains. Applied and Environmental Microbiology, 2010, 76, 2360-2365.	1.4	27
42	Multilocus Characterization Scheme for Shiga Toxin-Encoding Bacteriophages. Applied and Environmental Microbiology, 2007, 73, 8032-8040.	1.4	35
43	Short-Tailed Stx Phages Exploit the Conserved YaeT Protein To Disseminate Shiga Toxin Genes among Enterobacteria. Journal of Bacteriology, 2007, 189, 7223-7233.	1.0	68
44	Identification of multiple integration sites for Stx-phage $\hat{l} 24B$ in the Escherichia coli genome, description of a novel integrase and evidence for a functional anti-repressor. Microbiology (United) Tj ETQq0 0	0 rg θΤ 7/Ον	erloæda 10 Tf 50
45	Survival of a Shiga toxin-encoding bacteriophage in a compost model. FEMS Microbiology Letters, 2005, 245, 369-375.	0.7	31
46	Immunity Profiles of Wild-Type and Recombinant Shiga-Like Toxin-Encoding Bacteriophages and Characterization of Novel Double Lysogens. Infection and Immunity, 2003, 71, 3409-3418.	1.0	80